Skip to content

Effects of Remimazolam and Ciprofol TIVA on PRAE in Pediatric Tonsillectomy and Adenoidectomy

Effects of Remimazolam and Ciprofol Total Intravenous Anesthesia on Perioperative Respiratory Adverse Events in Pediatric Tonsillectomy and Adenoidectomy: A Randomized Controlled Study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07118579
Enrollment
114
Registered
2025-08-12
Start date
2025-09-23
Completion date
2026-08-31
Last updated
2025-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tonsillectomy With or Without Adenoidectomy

Keywords

Remimazolam, Ciprofol, TIVA, PRAE

Brief summary

To observe the effects of remimazolam versus ciprofol TIVA on PRAE in pediatric tonsillectomy and adenoidectomy.

Detailed description

To observe the effects of remimazolam versus ciprofol TIVA on PRAE in pediatric tonsillectomy and adenoidectomy, aiming to enhance surgical safety and improve postoperative outcomes in pediatric patients.

Interventions

DRUGRemimazolam

remimazolam induction (0.3-0.5 mg/kg) + maintenance (1-3 mg/kg/h)

DRUGPropofol

Anesthesia induction (2-3 mg/kg) + Anesthesia maintenance (6-10 mg/kg/h)

DRUGCiprofol

Anesthesia induction (0.4-0.5 mg/kg) + Anesthesia maintenance (0.8-1.2 mg/kg/h)

Sponsors

Tongji Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
2 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

* Aged 2-12 years * ASA physical status I-II * Body mass index (BMI): 14-28 kg/m² * Scheduled for elective tonsillectomy with or without adenoidectomy * Signed informed consent by legal guardian(s) and assent by children (≥8 years old)

Exclusion criteria

* History of severe pulmonary diseases (e.g., asthma, bronchiectasis, severe OSA) * Previous episodes of significant PRAEs * Documented drug allergies (e.g., to remimazolam, propofol, or ciprofol) * Comorbidities including: Uncorrected congenital heart disease, neuromuscular disorders, Developmental delay, Abnormal hepatic/renal function * Preoperative moderate-to-severe respiratory infections requiring surgery postponement * Recent participation in other clinical trials

Design outcomes

Primary

MeasureTime frameDescription
The incidence of perioperative respiratory adverse events5daysThe perioperative respiratory adverse events including: laryngospasm, bronchospasm, severe cough, oxygen desaturation, airway obstruction.

Secondary

MeasureTime frameDescription
Emergence time1 dayFrom anesthetic discontinuation to eye opening on command
Extubation time1 dayFrom anesthetic discontinuation to endotracheal tube removal
Anesthesia duration1 dayFrom anesthesia induction to discontinuation of anesthetics
The modified Aldrete score1 dayUpon admission to the PACU, the child was assessed using the modified Aldrete score, which ranges from 0 to 10. A higher score indicates a better recovery status.
doses of drugs24 hoursTotal sedative/analgesic consumption
PACU stay duration1 dayFrom PACU admission to meeting discharge criteria

Countries

China

Contacts

Primary ContactPu Zhou
tongjihlunli@163.com02783663625
Backup ContactAihua Du
70663307@qq.com02783663625

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026